A technology for quantifying and targeting cellular NADPH metabolism for disease diagnosis and therapeutic intervention

Background

NADPH (nicotinamide adenine dinucleotide phosphate) is a crucial cofactor in cellular metabolism, playing an essential role in biosynthetic reactions and the maintenance of redox balance. In mammalian cells, NADPH is required for the synthesis of fatty acids, nucleotides, and for the detoxification of reactive oxygen species. The demand for NADPH is particularly high in rapidly proliferating cells, such as cancer cells, which rely on robust biosynthetic and antioxidant systems to support growth and survival. Traditionally, the oxidative pentose phosphate pathway (oxPPP) has been considered the primary cytosolic source of NADPH, with additional contributions from enzymes like malic enzyme and isocitrate dehydrogenase. However, the complexity of cellular metabolism and the need to accurately assess NADPH production in different physiological and pathological states have highlighted the importance of understanding all contributing pathways, especially in the context of cancer and metabolic diseases where redox homeostasis is frequently disrupted.

Despite advances in metabolic research, current approaches to measuring and manipulating NADPH production suffer from significant limitations. Conventional methods often lack the resolution to distinguish between the various cellular sources of NADPH, particularly between cytosolic and mitochondrial compartments. Most techniques rely on indirect measurements or steady-state metabolite levels, which do not capture dynamic metabolic fluxes or pathway-specific contributions. This lack of specificity hampers the ability to diagnose diseases characterized by altered NADPH metabolism, such as cancer, and limits the development of targeted therapies that exploit metabolic vulnerabilities. Furthermore, existing therapeutic strategies targeting NADPH production, such as anti-folate drugs, can cause substantial toxicity in normal tissues due to their broad effects, underscoring the need for more selective and quantitative approaches to both diagnosis and treatment.

Technology

This technology centers on the identification and quantitative analysis of the 10-formyl-tetrahydrofolate (10-formyl-THF) pathway as a major source of NADPH in mammalian cells, particularly in the context of cancer and metabolic diseases. By employing advanced isotope tracer techniques—using deuterium- and carbon-labeled substrates such as serine, glucose, and succinate—the system tracks the incorporation of isotopes into NADPH via liquid chromatography-mass spectrometry (LC-MS) and mathematical flux modeling. These methods allow for precise differentiation between cytosolic and mitochondrial NADPH production, enabling the detection of altered metabolic fluxes associated with disease states. The technology further integrates therapeutic strategies, combining anti-folate agents with metabolic rescue compounds to selectively disrupt NADPH-dependent processes in proliferating cells while minimizing harm to healthy tissues. Companion diagnostic kits and in vivo imaging approaches are also included, facilitating real-time monitoring and assessment of metabolic pathway activity in both research and clinical settings.

What differentiates this technology is its comprehensive and quantitative approach to mapping NADPH metabolism, moving beyond traditional reliance on the oxidative pentose phosphate pathway. The use of multiple, specifically labeled isotope tracers and sophisticated mathematical modeling provides unparalleled resolution in distinguishing the contributions of various metabolic pathways to NADPH pools in different cellular compartments. This enables not only the diagnosis and prognosis of cancer and metabolic diseases based on unique metabolic signatures but also the tailoring and monitoring of therapeutic interventions with high specificity. The integration of diagnostic and therapeutic modalities—supported by robust experimental validation in cell models—positions this technology as a versatile platform for both fundamental research and precision medicine, offering actionable insights into cellular redox balance and metabolic vulnerabilities.

Benefits

• Enables precise quantification of NADPH production pathways in mammalian cells using isotope tracers and advanced analytical methods.
• Facilitates improved cancer diagnosis and prognosis by detecting altered NADPH metabolic fluxes specific to proliferating tumor cells.
• Supports real-time monitoring of therapeutic efficacy through measurement of isotope incorporation into NADPH and downstream metabolites.
• Provides targeted therapeutic strategies combining anti-folate agents with metabolic rescue compounds to selectively disrupt cancer cell metabolism while reducing systemic toxicity.
• Allows differentiation between cytosolic and mitochondrial NADPH production, aiding in personalized treatment approaches.
• Applicable to metabolic disease assessment, including diabetes and obesity, by evaluating NADPH pathway alterations.
• Includes development of companion diagnostic kits and imaging methods for clinical and research use.

Applications

• Cancer metabolic diagnostics
• Therapy response monitoring
• Targeted cancer combination therapies
• Metabolic disease assessment
• Companion diagnostic kit development

Additional info

This technology identifies 10-formyl-tetrahydrofolate oxidation via MTHFD as a major NADPH source. Utilizing deuterium and carbon tracers with liquid chromatography-mass spectrometry and flux modeling, it quantifies cytosolic and mitochondrial metabolic activity. These methods facilitate cancer diagnosis and therapeutic strategies combining anti-folate agents with rescue compounds to selectively disrupt redox defense in proliferating cells, minimizing systemic toxicity while targeting altered metabolic fluxes.